EHop-016, a NSC23766 structure-based Rac inhibitor effective at therapeutically achievable doses, slows tumor metastasis and angiogenesis in breast cancer cell lines by blocking Rac interaction with the GEF Vav. Here, AKT1 is linked to breast cancer.